Cogent Biosciences (NASDAQ:COGT) Reaches New 12-Month Low – What’s Next?

Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday. The stock traded as low as $27.69 and last traded at $27.65, with a volume of 356,312 shares traded. The stock had previously closed at $28.56.

Analysts Set New Price Targets

Several research firms recently commented on COGT. Piper Sandler boosted their price objective on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, October 2nd. HC Wainwright lifted their target price on shares of Cogent Biosciences from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Guggenheim upped their price target on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cogent Biosciences has an average rating of “Moderate Buy” and an average price target of $53.57.

Read Our Latest Research Report on Cogent Biosciences

Cogent Biosciences Trading Down 3.4%

The stock has a market cap of $4.80 billion, a PE ratio of -12.25 and a beta of 0.36. The business has a 50-day moving average of $31.39 and a 200 day moving average of $35.31. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.99 and a current ratio of 10.99.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last released its earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). Equities research analysts predict that Cogent Biosciences, Inc. will post -2.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Cogent Biosciences

A number of institutional investors have recently modified their holdings of COGT. BlackRock Inc. purchased a new stake in Cogent Biosciences in the 2nd quarter worth approximately $671,547,000. Wellington Management Group LLP lifted its stake in shares of Cogent Biosciences by 21.4% during the 2nd quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock worth $168,112,000 after purchasing an additional 765,355 shares during the period. Commodore Capital LP lifted its stake in shares of Cogent Biosciences by 31.5% during the 1st quarter. Commodore Capital LP now owns 2,888,007 shares of the technology company’s stock worth $111,159,000 after purchasing an additional 691,162 shares during the period. Pictet Asset Management Holding SA boosted its holdings in shares of Cogent Biosciences by 18.8% during the third quarter. Pictet Asset Management Holding SA now owns 2,842,776 shares of the technology company’s stock worth $90,990,000 after purchasing an additional 449,261 shares during the last quarter. Finally, Siren L.L.C. boosted its holdings in shares of Cogent Biosciences by 4.9% during the first quarter. Siren L.L.C. now owns 1,709,279 shares of the technology company’s stock worth $65,790,000 after purchasing an additional 80,000 shares during the last quarter.

Cogent Biosciences Company Profile

(Get Free Report)

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.

Further Reading

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.